Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices: https://www.marketbeat.com/logos/articles/med_20240710114454_chart-crsp-7102024ver001.png
3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices

Trading volume spikes in beaten-down stocks often signal a bottom for prices investors can bank on. The problem is that beaten-down stocks are usually in that position for a good reason, so it

3 Stock Giants Analysts Are Bullish On Despite Struggles: https://www.marketbeat.com/logos/articles/med_20240705084239_3-stock-giants-analysts-are-bullish-on-despite-str.jpg
3 Stock Giants Analysts Are Bullish On Despite Struggles

Despite their recent struggles, these three industry giants hold the promise of significant upside. With favorable consensus price targets and ratings, attractive P/E valuations, solid earnings

3 Stock Giants Analysts Are Bullish On Despite Struggles: https://www.marketbeat.com/logos/articles/med_20240705084239_3-stock-giants-analysts-are-bullish-on-despite-str.jpg
3 Stock Giants Analysts Are Bullish On Despite Struggles

Despite their recent struggles, these three industry giants hold the promise of significant upside. With favorable consensus price targets and ratings, attractive P/E valuations, solid earnings

AbbVie Stock: A Perfect Dip for Investors to Buy: https://www.marketbeat.com/logos/articles/med_20240703114110_abbvie-stock-a-perfect-dip-for-investors-to-buy.jpg
AbbVie Stock: A Perfect Dip for Investors to Buy

In a holiday-shortened week, shares of AbbVie Inc. (NYSE: ABBV) are down a little more than 3%. To put that in context, the drop in ABBV stock was more than that of biotech stocks such as Johnson

Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex: https://www.marketbeat.com/logos/articles/med_20240702093329_biotech-stock-breakout-ibb-eyes-major-resistance-l.jpg
Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex

The biotechnology sector, represented by the iShares Biotechnology ETF (NASDAQ: IBB), has experienced a year of consolidation. With the ETF up just 0.8%, it has underperformed the broader market

Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex: https://www.marketbeat.com/logos/articles/med_20240702093329_biotech-stock-breakout-ibb-eyes-major-resistance-l.jpg
Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex

The biotechnology sector, represented by the iShares Biotechnology ETF (NASDAQ: IBB), has experienced a year of consolidation. With the ETF up just 0.8%, it has underperformed the broader market

Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex: https://www.marketbeat.com/logos/articles/med_20240702093329_biotech-stock-breakout-ibb-eyes-major-resistance-l.jpg
Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex

The biotechnology sector, represented by the iShares Biotechnology ETF (NASDAQ: IBB), has experienced a year of consolidation. With the ETF up just 0.8%, it has underperformed the broader market

Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes: https://www.marketbeat.com/logos/articles/med_20240701132023_charty-pfe.jpg
Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes

Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy makers Novo Nordisk A/S (NYSE: NVO) a

Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes: https://www.marketbeat.com/logos/articles/med_20240701132023_charty-pfe.jpg
Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes

Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy makers Novo Nordisk A/S (NYSE: NVO) a

Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market: https://www.marketbeat.com/logos/articles/med_20240630174256_charty-lly.jpg
Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market

Global pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound. Mounjaro is prescribed for Type 2 diabetes but is

Sarepta Therapeutics Stock Soars on FDA Approval: https://www.marketbeat.com/logos/articles/med_20240621103734_sarepta-therapeutics-stock-soars-on-fda-approval.jpg
Sarepta Therapeutics Stock Soars on FDA Approval

Sarepta Therapeutics (NASDAQ: SRPT) is leading the game in precision genetic medicine and biotechnology. Sarepta Therapeutics' stock price has witnessed a surge of over 40% after receiving

Top 4 Large-Cap Stocks With Major Short Interest: https://www.marketbeat.com/logos/articles/med_20240612135212_top-4-large-cap-stocks-with-major-short-interest.jpg
Top 4 Large-Cap Stocks With Major Short Interest

With the ongoing GameStop saga reigniting interest in meme stocks, investors, or more likely traders and speculators, are once again seeking out stocks with high short interest. As the overall

Can Viking Holdings Extend Gains from Affluent Cruisers?: https://www.marketbeat.com/logos/articles/med_20240610131935_can-viking-holdings-extend-its-gains-from-affluent.jpg
Can Viking Holdings Extend Gains from Affluent Cruisers?

Destination-focused luxury cruise operator Viking Holdings Ltd. (NYSE: VIK) went public through a $1.8 billion initial public offering (IPO) on May 1, 2024. It was priced at $24 and hasn’t

HealthEquity Stock: Leading Health Savings Account Investment: https://www.marketbeat.com/logos/articles/med_20240609114559_chart-hqy.jpg
HealthEquity Stock: Leading Health Savings Account Investment

HealthEquity Inc (NASDAQ: HQY) is one of the nation’s largest providers of health savings accounts (HSA) and consumer-directed benefits (CDB) services. Its platform enables individuals to open

Geron Corporation: FDA Approval Fuels Stock Price Surge: https://www.marketbeat.com/logos/articles/med_20240607114957_geron-corporation-fda-approval-fuels-stock-price-s.jpg
Geron Corporation: FDA Approval Fuels Stock Price Surge

The recent FDA approval of RYTELO™ (imetelstat) has propelled Geron Corporation (NASDAQ: GERN) into the spotlight, sparking a surge in Geron’s stock price and attracting heightened attention

Novavax Stock’s Recent Surge and Future Potential: https://www.marketbeat.com/logos/articles/med_20240606112435_novavax-stocks-recent-surge-and-future-potential.jpg
Novavax Stock’s Recent Surge and Future Potential

Novavax (NASDAQ: NVAX) is a drug and vaccine manufacturer in the healthcare sector known for its efforts in the COVID-19 vaccine market. Novavax’s stock price has experienced a remarkable surge

Centene Reaffirms Guidance, But Is it Too Late?: https://www.marketbeat.com/logos/articles/med_20240602155058_chart-cnc.jpg
Centene Reaffirms Guidance, But Is it Too Late?

Managed care health insurance company Centene Inc. (NYSE: CNC) recently saw its share rebound after reaffirming its guidance. This move came just after UnitedHealth Group Inc. (NYSE: UNH) made

Hims & Hers Health Soars on Generic GLP-1 Rollout Plans: https://www.marketbeat.com/logos/articles/med_20240602154511_charte-hims.jpg
Hims & Hers Health Soars on Generic GLP-1 Rollout Plans

Him & Hers Health Inc. (NYSE: HIMS) provides a direct-to-consumer (DTC) health and wellness platform. The company was best known for prescribing treatments for erectile dysfunction (ED) through

Hims & Hers Health Soars on Generic GLP-1 Rollout Plans: https://www.marketbeat.com/logos/articles/med_20240602154511_charte-hims.jpg
Hims & Hers Health Soars on Generic GLP-1 Rollout Plans

Him & Hers Health Inc. (NYSE: HIMS) provides a direct-to-consumer (DTC) health and wellness platform. The company was best known for prescribing treatments for erectile dysfunction (ED) through

Is Cigna Group the Nation's Best-Run Health Insurance Company?: https://www.marketbeat.com/logos/articles/med_20240525153829_chart-ci.jpg
Is Cigna Group the Nation's Best-Run Health Insurance Company?

Health insurance companies in the medical sector have not fared well in 2024. Medicare Advantage (MA) plans were a bountiful source of income until the second half of 2023. Humana Inc. (NYSE: HUM)

Medtronic Dips: Is Now the Time to Buy?: https://www.marketbeat.com/logos/articles/med_20240523121523_chart-mdt-5232024ver001.png
Medtronic Dips: Is Now the Time to Buy?

Shares of Medtronic (NYSE: MDT) are falling following its FQ4 release and guidance, opening up a potential buying opportunity. The question is whether its value, yield, balance sheet and cash flow

2 Stocks Providing Medical Insurance for Your Pets: https://www.marketbeat.com/logos/articles/med_20240519155501_chart-trup.jpg
2 Stocks Providing Medical Insurance for Your Pets

The pandemic triggered a surge in pet ownership as social distancing and lockdowns resulted in the need for companionship for many individuals and families. Anyone who owns a dog or cat can

Will the Biotech Sector Shift From Lagger to Leader?: https://www.marketbeat.com/logos/articles/med_20240509132613_will-the-biotech-sector-shift-from-lagger-to-leade.jpg
Will the Biotech Sector Shift From Lagger to Leader?

The biotech sector and its popular ETF, the iShares Biotechnology ETF (NASDAQ: IBB), have lagged the overall market during the year, with its shares slightly red. However, in recent weeks, the

Will the Biotech Sector Shift From Lagger to Leader?: https://www.marketbeat.com/logos/articles/med_20240509132613_will-the-biotech-sector-shift-from-lagger-to-leade.jpg
Will the Biotech Sector Shift From Lagger to Leader?

The biotech sector and its popular ETF, the iShares Biotechnology ETF (NASDAQ: IBB), have lagged the overall market during the year, with its shares slightly red. However, in recent weeks, the

Will the Biotech Sector Shift From Lagger to Leader?: https://www.marketbeat.com/logos/articles/med_20240509132613_will-the-biotech-sector-shift-from-lagger-to-leade.jpg
Will the Biotech Sector Shift From Lagger to Leader?

The biotech sector and its popular ETF, the iShares Biotechnology ETF (NASDAQ: IBB), have lagged the overall market during the year, with its shares slightly red. However, in recent weeks, the